99 related articles for article (PubMed ID: 27375212)
1. Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review.
Folgori L; Bielicki J; Ruiz B; Turner MA; Bradley JS; Benjamin DK; Zaoutis TE; Lutsar I; Giaquinto C; Rossi P; Sharland M
Lancet Infect Dis; 2016 Sep; 16(9):e178-e189. PubMed ID: 27375212
[TBL] [Abstract][Full Text] [Related]
2. Standardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA-ID network view.
Folgori L; Lutsar I; Standing JF; Walker AS; Roilides E; Zaoutis TE; Jafri H; Giaquinto C; Turner MA; Sharland M
BMJ Open; 2019 Dec; 9(12):e032592. PubMed ID: 31892658
[TBL] [Abstract][Full Text] [Related]
3. Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans.
Piana C; Kliphuis E; Della Pasqua O
Clin Trials; 2013 Apr; 10(2):269-79. PubMed ID: 23335676
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.
Tillotson GS; Echols RM
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S237-40. PubMed ID: 18986296
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review.
Lee JS; Giesler DL; Gellad WF; Fine MJ
JAMA; 2016 Feb; 315(6):593-602. PubMed ID: 26864413
[TBL] [Abstract][Full Text] [Related]
6. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good.
Corey GR; Stryjewski ME
Clin Infect Dis; 2011 Jun; 52 Suppl 7():S469-76. PubMed ID: 21546623
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis.
Li JZ; Winston LG; Moore DH; Bent S
Am J Med; 2007 Sep; 120(9):783-90. PubMed ID: 17765048
[TBL] [Abstract][Full Text] [Related]
8. FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials.
Itani KM; Shorr AF
Clin Infect Dis; 2014 Jan; 58 Suppl 1():S4-9. PubMed ID: 24343831
[TBL] [Abstract][Full Text] [Related]
9. An analysis of reporting quality of prospective studies examining community antibiotic use and resistance.
Bakhit M; Del Mar C; Scott AM; Hoffmann T
Trials; 2018 Nov; 19(1):656. PubMed ID: 30482238
[TBL] [Abstract][Full Text] [Related]
10. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
11. Unique considerations in the evaluation of antibacterials in clinical trials for pediatric community-acquired pneumonia.
Bradley JS; McCracken GH
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S241-8. PubMed ID: 18986297
[TBL] [Abstract][Full Text] [Related]
12. FDA committee gives new antibiotic mixed endorsement.
Clin Infect Dis; 2001 Jun; 32(12):i. PubMed ID: 11441811
[No Abstract] [Full Text] [Related]
13. Systematic review on antibiotic therapy for pneumonia in children between 2 and 59 months of age.
Lassi ZS; Das JK; Haider SW; Salam RA; Qazi SA; Bhutta ZA
Arch Dis Child; 2014 Jul; 99(7):687-93. PubMed ID: 24431417
[TBL] [Abstract][Full Text] [Related]
14. Comments on: Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin and comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
Cifaldi MA
Curr Med Res Opin; 2004 Dec; 20(12):1895-6; author reply 1896-7. PubMed ID: 15701207
[No Abstract] [Full Text] [Related]
15. Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
Gilbert DN
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S121-2. PubMed ID: 18986276
[TBL] [Abstract][Full Text] [Related]
16. Reassessing the design, conduct, and analysis of clinical trials of therapy for community-acquired pneumonia.
Powers JH
Clin Infect Dis; 2008 Apr; 46(8):1152-6. PubMed ID: 18444849
[No Abstract] [Full Text] [Related]
17. Paediatric cardiovascular clinical trials: an analysis of ClinicalTrials.gov and the Food and Drug Administration Pediatric Drug Labeling Database.
Hill KD; Henderson HT; Hornik CP; Li JS
Cardiol Young; 2015 Aug; 25 Suppl 2(0 2):172-80. PubMed ID: 26377725
[TBL] [Abstract][Full Text] [Related]
18. Outpatient treatment of community-acquired pneumonia in adults.
Pomilla PV; Brown RB
Arch Intern Med; 1994 Aug; 154(16):1793-802. PubMed ID: 8053746
[TBL] [Abstract][Full Text] [Related]
19. International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 May; 66(93):24390-1. PubMed ID: 12356096
[TBL] [Abstract][Full Text] [Related]
20. How to reduce antibiotic consumption for community-acquired pneumonia?
Montassier E; Goffinet N; Potel G; Batard E
Med Mal Infect; 2013 Feb; 43(2):52-9. PubMed ID: 23433607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
